Sylvia McBrinn

Sylvia McBrinn has more than 35 years of leadership and commercialization experience in the biopharmaceutical industry having successfully launched products in a variety of therapeutic areas. Ms. McBrinn currently advises innovators at Yale University as an Entrepreneur in Residence and female entrepreneurs as a member of the Life Science Council of Springboard Enterprises. She was the founding CEO and a board director of Axerion Therapeutics, Inc. (now ReNetX Bio), a private clinical stage biotech company. Prior to that, she served as Head, U.S. Organization of Vernalis Pharmaceuticals, Inc. where she built and led its U.S. commercial organization, and as Executive Vice President of Andrx Laboratories, Inc. she was responsible for leading the branded pharmaceutical division. Ms. McBrinn began her career at Pfizer and predecessor companies, where she held commercial roles of increasing responsibility including Vice President, Global and US Marketing, Bextra, one of the top 10 launches at that point in time, Vice President, Global and US Marketing, Neurology, where she built the #1 Global Parkinson's disease Franchise and Vice President, Marketing, U.S. Market Company. Ms McBrinn also serves as a member of the board of directors of Ilya Pharma, AB, a clinical stage gene therapy company.

She received her B.S. in Biology from DeSales University and MBA from Widener University.